核医学显像在诊断淋巴瘤药物相关早期肺脏损伤中的研究进展  

Research progress of nuclear medicine imaging in the diagnosis of lymphoma drug-associated early lung injury

作　　者：赵彤 原凌[1] Zhao Tong;Yuan Ling(Department of Nuclear Medicine(PET/CT),Shanxi Province Cancer Hospital,Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences,Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,China;School of Forensic Medicine,Shanxi Medical University,Taiyuan 030013,China)

机构地区：[1]山西省肿瘤医院中国医学科学院肿瘤医院山西医院山西医科大学附属肿瘤医院核医学PET/CT中心,太原030013 [2]山西医科大学法医学院,太原030013

出　　处：《中华放射医学与防护杂志》2023年第11期939-943,共5页Chinese Journal of Radiological Medicine and Protection

基　　金：山西省“四个一批”引导性科技专项基金(2021XM49)。

摘　　要：药物相关肺脏损伤(DALI)是影响淋巴瘤患者预后的重要因素之一,早期识别并及时干预DALI至关重要。目前常用的影像学检查(高分辨CT)及实验室检查均具有滞后性,从而使肺脏损伤不可逆,而核医学显像对DALI提供了早于形态学改变之前的功能代谢信息,使患者获得及早干预。本文就核医学显像在淋巴瘤DALI中的应用进行综述。Drug-associated lung injury(DALI)is one of the important factors affecting the prognosis of patients with lymphoma,and early identification and timely intervention for DALI are essential.Currently,the commonly used imaging examinations,e.g.high-resolution computed tomography,and laboratory tests all have hysteresis,so that the lung injury may be irreversible.Nuclear medicine imaging provides functional and metabolic information for DALI before morphological changes,so that the opportunity for early clinical intervention can be obtained.This article reviews the application of nuclear medicine imaging in lymphoma DALI.

关 键 词：淋巴瘤 肺损伤 正电子发射断层显像术 

分 类 号：R733.1[医药卫生—肿瘤] R730.44[医药卫生—临床医学]